Conmed

Conmed Forward P/E

The Forward P/E Ratio of Conmed (CNMD) as of Oct 8, 2026 is 22.33. In the previous year, Forward P/E Ratio was 7.94 — a change of 181.42% (higher).

Forward P/E

22.33

YoY

181.42%

Last updated:

Forward P/E Ratio of Conmed is 2025 22.33 . Forward P/E Ratio of Conmed was 2024 7.94 . It decreases by 181.42% higher compared to the previous year.

The Conmed Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
25.72 USD
Jan 1, 2019
36.72 USD
Jan 1, 2020
110.41 USD
Jan 1, 2021
16.80 USD
Jan 1, 2022
-13.04 USD
Jan 1, 2023
16.30 USD
Jan 1, 2024
7.94 USD
Jan 1, 2025
22.33 USD
The Conmed Forward P/E history
YEARForward P/EYoY
22.33+181.42%
7.94-51.32%
16.30-225.01%
-13.04-177.61%
16.80-84.78%
110.41+200.73%
36.72+42.75%
25.72+35.82%
18.94-73.57%
71.66+107.98%
34.45+5.55%
32.64—
Access this data via the Eulerpool API

Conmed Stock analysis

What does Conmed do? Conmed Corporation is a leading medical technology company that offers a wide range of surgical instruments and devices for the fields of gastroenterology, endoscopy, orthopedics, gynecology, and electro surgery. The company was founded in 1970 and is headquartered in Utica, New York. The history of Conmed Corp began with the founding of Consolidated Medical Equipment, Inc. (CME) in 1970. The company initially started its business with the distribution of surgical instruments and devices for medical applications and quickly expanded in this field. In the 1980s, the company went public. In the 1990s, the company changed its name to Conmed Corporation and expanded its activities into the field of electro surgery, which has since become a major growth driver for the company. Today, Conmed Corp operates multiple manufacturing facilities worldwide and has sales offices in over 50 countries. The company is divided into four main business segments: gastroenterology, endoscopy, orthopedics, and electro surgery. The gastroenterology segment includes products for the diagnosis and treatment of gastrointestinal disorders, such as endoscopes, biopsy instruments, dilation balloons, trocars, and shears. In the endoscopy segment, Conmed Corp offers products for the diagnosis and treatment of digestive tract disorders, including endoscopes, biopsy instruments, dilation balloons, trocars, and shears. The orthopedics segment includes a wide range of surgical instruments and devices for the treatment of musculoskeletal disorders, including implants, bandages, bone plates, intramedullary nails, and others. Finally, the electro surgery segment is the fastest-growing segment of Conmed Corp and includes a wide range of devices for precision surgery, including electrocautery, electro surgery, endoscopy, and laparoscopy devices. Conmed Corp aims to develop innovative medical technologies that meet the needs of patients and healthcare professionals. The company places great emphasis on producing high-quality products that are reliable and safe. Conmed Corp is a successful company that continues to evolve and expand its product range to meet the rapidly evolving needs of the medical community. Conmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Conmed stock

Forward P/E Ratio of Conmed is 22.33 in 2025.

Forward P/E Ratio of Conmed changed from 7.94 to 22.33, representing a 181.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Conmed since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Conmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Conmed

All Key Metrics — Conmed